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The emergence of multiple novel agents targeting distinct path-
ways in the last several years have caused a paradigm shift in the
management of advanced prostate cancer. With evidence of clinically
meaningful efﬁcacy, these agents when coupled with proper
sequencing and used in a multidisciplinary care setting could provide
patients with better survival whilst maintaining good quality of life.
2. The changing paradigms in prostate cancer
Prostate cancer is the main cause of cancer-related mortality
among men. And although surgery and radiation have been suc-
cessful treatments, between 30% and 40% of prostate cancer pa-
tients progress to advanced forms of the disease.1 Almost all
patients with metastatic prostate cancer go on to develop
castration-resistant prostate cancer (CRPC).2
From2004 to 2010, docetaxel-based chemotherapywas the only
approved agent for the treatment of metastatic CRPC.3,4 Never-
theless, signiﬁcant advances in the understanding of the androgen
pathway role over the last decade have led to the development of
alternative novel hormonal agents such as abiraterone and enza-
lutamide to treat advanced castration-resistant prostate cancer.
Both agents target the androgen axis but with distinct mechanisms
of action. Abiraterone inhibits the synthesis of androgen by block-
ing cytochrome P450 17, while enzalutamide inhibits the androgen* Corresponding author: Hideyuki Akaza (akazah@med.rcast.u-tokyo.ac.jp).
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mutations such as BRCA2, and now evidence for somatic aberration
in these DNA damage response pathways, is opening up further
treatment options in mCRPC.
With this increase in knowledge, therapeutic options for pa-
tients are expanding leading to improvements in overall survival,3
signiﬁcantly changing the standard of care for the disease. These
innovations in understanding the molecular evolution of mCRPC
could potentially provide physicians the ability to do targeted
screening of patients at risk as well as stratify patients according to
molecular subtypes for different management strategies.6
Despite this major development in the ﬁeld, androgen depri-
vation therapy (ADT) remains the backbone treatment for advanced
prostate cancer.3. Novel agents as systemic treatments
Metastatic prostate cancer and CRPC can be managed with a
range of treatments including secondary hormonal therapies,
which are associated with good outcomes when used in combi-
nationwith ADT. Treatments for patients are chosen based on prior
therapy, symptom burden, type of metastases, performance status,
comorbidities, adverse event proﬁles, patient preference, and
treatment sequence.5
Treatment sequencing is an important consideration as some
agents can affect a patient’s responses to subsequent therapeutic
strategies,5 as well as the achievement of prolonged remissions.7
With the emergence of novel agents, the next stage in research
will be to determine appropriate and cost-effective ways of
sequencing available agents to provide patients with greater
beneﬁt, as well as to validate biomarkers that select agents that
elicit the best response in individual patients.
Novel AR-directed therapies have demonstrated improved
overall survival in metastatic CRPC patients.5 Some of these novel
agents have shown promising results when used earlier in the
natural history of the disease and have the potential to radically
alter the current treatment pathway paradigms. Patients with
metastatic CRPC who were symptomatic or mildly symptomaticy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 3 (2015) S1eS4S2chemotherapy-naïve on abiraterone and prednisone had longer
overall survival compared with patients on placebo plus predni-
sone.8 Enzalutamide also provided improved overall survival out-
comes for the same type of patient populations compared to
placebo.9
Within the US setting, abiraterone does not appear to signiﬁ-
cantly impact healthcare cost allocation due to the small number of
patients eligible for treatment and the lower incidences of toxicity
compared to chemotherapy.10e12 Nevertheless, a better under-
standing of the beneﬁts of these costly novel treatments in asso-
ciation to its full cost which include the cost of treating adverse
events is needed.
4. A collaborative approach to disease management
As treatment for prostate cancer should be speciﬁc to the patient
and his speciﬁc cancer,13 the involvement of a multidisciplinary
team involving the urologist, (molecular) oncologist, (molecular)
pathologist, and radiologist is recommended.14 The adoption of
multidisciplinary teamshave increasedworldwide, and this strategy
has beneﬁted both patients and healthcare professionals.15 In one
study, patients on themultidisciplinaryarmhad similar outcomes as
patients on the standard evaluation despite having higher-risk dis-
ease.16 The same study also found that a multidisciplinary approach
did not cause delay in time to radical prostatectomy.16 Nevertheless,
as this approach could be time consuming and resource intensive,
prioritising cases by disease complexity, tumour type, or the avail-
ability of members could be a feasible way of incorporating it into
patient care.15 Another study has also shown that weekly evalua-
tions with the different specialists doing patient consultations,
going through the data, and discussing management strategies
within a single day to be practical.17
5. The 4th Asia Paciﬁc Prostate Cancer Conference
In view of the evolving paradigms in prostate cancer manage-
ment, particularly with the advent of novel therapeutic agents, it is
important to provide a platform to debate current data. The 4th Asia
Paciﬁc Prostate Cancer Conference is a forum for regional urologists
and oncologists with a special interest in the management of
prostate cancer to discuss the applicability of such data in day-to-
day practice.
Building on the success of conferences past, the theme of this
year's Asia Paciﬁc Prostate Cancer Conference was Emerging Per-
spectives in Prostate Cancer (EPiC). Hosted by the Academy for
Cancer Education (ACE) and endorsed by the Asia Paciﬁc Prostate
Society (APPS) as well as the Asia Paciﬁc Society of Uro-Oncology
(APSU), this meeting is becoming one of the important medical
educational meetings for clinicians involved in the treatment of
advanced prostate cancer in this region. For the fourth time, the
conference served as a timely platform for valuable exchanges
between prostate cancer care providers from different specialties
practising in either reimbursed or self-pay healthcare systems. The
Japanese health system, for example, delivers one of the largest
universal coverage in Asia Paciﬁc and has been providing signiﬁcant
subsidy and access of novel agents to CRPC patients.
This EPiC meeting provided an overview of the latest clinical
data and pharmacoeconomic principles within the context of
advanced prostate cancer. The participants deliberated on
updated data and practice principles in relation to real-world
resource-stratiﬁed practices in the Asia Paciﬁc. A steering com-
mittee of experts was convened in August 2014 to guide the
development of this year’s meeting agenda. This ensured that thescientiﬁc content of this meeting were driven by the educational
needs of clinicians in the region. The conference showcased an
impressive faculty of 20 highly sought after regional key opinion
leaders and included didactic lectures, case study presentations,
debates on pertinent topics as well as open panel conversations
with the faculty.
The meeting was also an avenue for cross-country and multi-
disciplinary interactions among clinicians across Asia Paciﬁc, with
the participation of 172 delegates from 12 countries (Australia,
China, Hong Kong, Indonesia, India, Japan, Malaysia, Singapore,
South Korea, Taiwan, Thailand, and Vietnam). As host, Japan
comprised 63% of the audience. Majority of the participants were
urologists (91%), and the rest were oncologists. Most of them served
in the public sector (80%). In addition, the debates and case study
sessions were broadcasted live to 19 sites across India, Nepal and
Bangladesh; reaching in excess of 160 urologist and oncologist
viewers. Viewers were able to make comments and questions in
real time. Selected questions were also addressed live by the panel
of experts at the conference.
The abstracts of presentations at the 4th Asia Paciﬁc Prostate
Cancer Conference could be found in this supplement.6. Prostate care management practices in Asia Paciﬁc:
Findings of a pre-meeting survey
One hundred and eighteen participants from countries repre-
sented at the 4th Asia Paciﬁc Prostate Cancer Conference responded
to the survey. As almost a quarter of the respondents (37%) were
Japanese delegates, the results from the individual countries other
than Japan are limited by small sample sizes. Majority of the re-
spondents worked in the public sector (73%) and were urologists
(82%). Seventy percent had more than 10 years of experience in
treating prostate cancer.
According to the responses, the majority (78%) indicated that
CRPC comes under the care of the urologist in their respective
countries; only 19% indicated that oncologists were primarily
responsible for the care of CRPC patients. A small number (2%)
indicated both specialties were responsible.
Participants indicated that the main reason for the increasing
incidence of prostate cancer in the countries was the ageing pop-
ulation. Other major factors were the increase in demand for
testing and screening as well as heightened disease awareness.
In the pre-meeting survey, delegates were also given patient
scenarios to consider. For a patient with 10 years life expectancy
and intermediate risk for localised prostate cancer (Gleason score of
7), 34% of respondents indicated that they would opt for robotic
radical prostatectomy as ﬁrst-line therapy. 27% chose radical
radiotherapy, with or without ADT, and 14% chose laparoscopic
radical prostatectomy. Stratiﬁcation by countries revealed differ-
ences in practices across the region. Robotic radical prostatectomy
was the main treatment of choice for these types of patients in
Japan, Singapore, and Taiwan; but not so in Thailand, Vietnam, and
China.
This difference between countries in the Asia Paciﬁc region is
also seen in terms of the therapies reimbursed by the government
healthcare system. Singapore had the most number of therapies
approved while Vietnam had the least number of therapies reim-
bursed. In terms of novel agents for the treatment of prostate
cancer, abiraterone was approved in all countries surveyed and
reimbursed in Japan for all CRPC patients and in Taiwan for some
CRPC patients. Whereas enzalutamide was approved in Singapore
and Japan, it was under ﬁling in Taiwan, Vietnam and Indonesia,
and undergoing clinical trial in China.
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adjuvant chemotherapy for all patients with hormone-sensitive
metastatic prostate cancer but more than half would opt for this
only if the patients had a heavy burden of metastases. The survey
revealed that clinicians in Taiwan and Singapore mainly reserved
adjuvant chemotherapy for patients with a heavy burden of me-
tastases. In Japan and Thailand, more than half would never
consider the treatment for hormone-sensitive patients. In Vietnam,
half of the respondents would not consider it, while the other half
would use it for all hormone-sensitive patients.
The majority of the respondents (75%) would use a combination
of prostate-speciﬁc antigen (PSA) tests, imaging, and clinical
symptoms to diagnose progression of prostate cancer in their
practices. Twenty three percent would only base their diagnosis on
PSA test results. A small number of physicians from Japan and
Thailand used imaging. Forty percent of physicians would diagnose
a patient with CRPC when he fails combined androgen blockade
(CAB). This was speciﬁcally the approach in Singapore and Japan. At
least half of the physicians in Thailand, Taiwan, and Vietnamwould
diagnose a patient with CRPC if he failed luteinising hormone-
releasing hormone (LHRH) or gonadotropin-releasing hormone
(GnRH).
The majority (81%) of the physicians were aware that prostate
cancer cells create androgen to grow themselves. Many were also
familiar with other CRPC mechanisms.
Forty four percent would use docetaxel plus prednisone as ﬁrst-
line treatment for symptomatic metastatic CRPC, while 20% would
use abiraterone plus prednisone, and 17% would opt for ADT.
Analysed by country, the survey results show that Thailand had the
highest number of physicians (44%) who would consider using
abiraterone plus prednisone ﬁrst-line, while in Taiwan, only 8% of
the physicians would consider the combination as ﬁrst-line due to
its reimbursement policy for post-chemo usage.
When asked about the various approaches used to treat symp-
tomatic bone metastases in patients with metastatic CRPC, more
physicians (66%) would provide palliative care in a post-
chemotherapy setting than in the pre-chemotherapy setting
(42%). This trend was seen in all countries except in Taiwan and
Thailand. In Taiwan, although less than half of the physicians would
provide palliative care for patients in either setting, slightly more
physicians would provide palliative care before chemotherapy than
after. In Thailand, 71% of physicians would provide palliative care in
both settings. The biggest disparity in the provision of palliative
care services between pre- and post-chemotherapy settings were
seen in Japan (28% vs. 72%).
Finally, when asked about their approach when a symptomatic,
mCRPC patient with good performance status and prior docetaxel
chemotherapy refuses treatment that is expected to produce good
treatment outcomes due to high medical costs, 62% would try to
persuade the patient to receive the treatment if he has more than
10 years life expectancy. If the patient is expected to live for less
than 10 years, 35% would treat with a cheaper existing agent while
expecting poorer outcomes and 31% would offer palliative care.
Nevertheless, 28% would still persuade the patient to try for the
better treatment option. Life expectancy appears to be an impor-
tant determinant for treatment in Japan. Three-in-four Japanese
urologist or oncologist would persuade patients with a ‘long life
expectancy’ (>10 years) to receive the treatment associated that
conferred ‘better outcomes’ even if it was the more expensive
treatment. Only 27% would do so if the patients had a ‘short life
expectancy’ (<10 years). Interestingly, despite having universal
healthcare coverage in the country, Japan also had the most num-
ber of physicians willing to treat with cheaper drugs if the patienthad a short life expectancy than all other countries. If the patient
has many more years to live, however, Japanese physicians were
less likely than physicians from other countries to use the cheaper
agent. In self-pay healthcare systems such as Singapore and
Thailand, physicians would try to persuade patients to receive the
treatment associated with ‘better outcomes’ in spite of ﬁnancial
constraints. In Vietnam, only 30 e 33% of the physicians would
persuade the patient to receive the higher costing treatment even if
it was associated with ‘better outcomes’, regardless of the patient's
life expectancy.
It should be noted that these results were obtained from a pre-
meeting survey conducted prior to the 4th Asia Paciﬁc Prostate
Cancer Conference. The results provide a snapshot of management
practices of participants from across Asia Paciﬁc countries repre-
sented at the conference; and interestingly contrast with some of
the results from the 1st APCCC in St. Gallen, which involved 41
panelists mainly from the US and EU, who made recommendations
for advanced prostate cancer.18 These ﬁndings also do not represent
management practices of all clinicians within speciﬁc countries
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